Jan 2023 $10 M Private placement after listing $10 to $50 million 1
Hoth Therapeutics, Inc.: Private sale, Jan 2023 × Investors in this round 1 investor had bought by the notice of Jan 4, 2023: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Hoth Therapeutics, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $10 M of $10 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $700,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Nevada People named in the notice David Briones · Executive Officer · Chief Financial Officer Robb Knie · Executive Officer, Director · Chief Executive Officer and President David Sarnoff · Director Graig Springer · Director Jeff Pavell · Director Wayne Linsley · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. Wainwright & Co., LLC (CRD 375) · New York, New York Sold in NY Remarks in the notice On fees: “Represents a fee of 7% of the gross proceeds from the sale of securities. Excludes (i) a management fee of $100,000; (ii) non-accountable expenses of $20,000; (iii) accountable expenses of $50,000; and (iv) 100,000 placement agent warrants.”Signed by Robb Knie, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 4, 2023. Read the notice at the SEC .
equity, options SEC Mar 2021 $15 M Private placement after listing $10 to $50 million 13
Hoth Therapeutics, Inc.: Private sale, Mar 2021 × Investors in this round 13 investors had bought by the notice of Mar 16, 2021: 13 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Hoth Therapeutics, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $15 M of $15 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $1,050,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Nevada People named in the notice David Briones · Executive Officer · Chief Financial Officer Robb Knie · Executive Officer, Director · Chief Executive Officer and President Stefanie Johns · Executive Officer · Chief Scientific Officer David Sarnoff · Director Graig Springer · Director Vadim Mats · Director Wayne Linsley · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round H.C. Wainwright & Co., LLC (CRD 375) · New York, New York Sold in IL, NJ, NY Remarks in the notice On fees: “Represents a fee of 7% of the gross proceeds from the sale of securities. Excludes (i) a management fee of $150,000; (ii) non-accountable expenses of $35,000; (iii) accountable expenses of $50,000; and (iv) 379,747 placement agent warrants.”Signed by Robb Knie, Chief Executive Officer. Source: SEC Form D, newest notice filed Mar 16, 2021. Read the notice at the SEC .
equity, options SEC Jan 2021 $5 M Private placement after listing $2 to $10 million 3
Hoth Therapeutics, Inc.: Private sale, Jan 2021 × Investors in this round 3 investors had bought by the notice of Jan 8, 2021: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Hoth Therapeutics, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $5 M of $5 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $350,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions as estimates
The company Corporation, incorporated in Nevada People named in the notice David Briones · Executive Officer · Chief Financial Officer Robb Knie · Executive Officer, Director · Chief Executive Officer and President Stefanie Johns · Executive Officer · Chief Scientific Officer David Sarnoff · Director Graig Springer · Director Vadim Mats · Director Wayne Linsley · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round The Benchmark Company, LLC (CRD 22982) · New York, New York Sold in CA, IL, NY Remarks in the notice On fees: “Represents a fee of 7% of the gross proceeds from the sale of securities. Excludes reimbursement of legal expenses in the amount of $50,000 and placement agent warrants to purchase common stock equal to 5% of the securities issued in the offering.”Signed by Robb Knie, Chief Executive Officer. Source: SEC Form D, newest notice filed Jan 8, 2021. Read the notice at the SEC .
equity, options SEC Aug 2019 $2 M No. 2 $2 to $10 million 53
Hoth Therapeutics, Inc.: Raise no. 2, Aug 2019 × Investors in this round 53 investors had bought by the notice of Aug 21, 2019: 53 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Hoth Therapeutics, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $2 M of $5 M offered; $3 M still to sell
Smallest investment taken $10,000
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $294,455
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Nevada People named in the notice David Briones · Executive Officer Robb Knie · Executive Officer, Director Anthony Hayes · Director David B. Sarnoff · Director Kenneth Rice · Director Vadim Mats · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New York Sold in CA, FL, GA, IL, KY, LA, MA, MI, NC, NY, OK, PA, TX, UT, and outside the US Remarks in the notice On fees: “Laidlaw will also receive warrants to purchase such number of shares of common stock equal to 10% of the number of shares of common stock sold in the offering, including shares of common stock issuable upon exercise of warrants sold in the offering.”Signed by Robb Knie, Chief Executive Officer. Source: SEC Form D, newest notice filed Aug 21, 2019. Read the notice at the SEC .
equity, options SEC Oct 2017 $1 M No. 1 Under $2 million 5
Hoth Therapeutics, Inc.: Raise no. 1, Oct 2017 × Investors in this round 5 investors had bought by the notice of Nov 7, 2017: 5 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round. 2 investors are named for Hoth Therapeutics, Inc. as a whole in other filings: see Investors below.
What the notice says
Amount sold $1 M of $5 M offered; $4 M still to sell
Smallest investment taken $10,000
What was sold options or other rights to buy securities, securities to be acquired by exercising them, other: convertible preferred stock and warrants to purchase common stock Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $650,000
Finders' fees none
Paid to its own people $150,000 (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks sales commissions and payments to its own people as estimates
The company Corporation, incorporated in Nevada People named in the notice Robb Knie · Executive Officer, Director, Promoter · President and Chief Executive Officer Anthony Hayes · Director Kenneth Rice · Director Vadim Mats · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Laidlaw & Company (UK) Ltd. (CRD 119037) · New York, New York Sold in CO, ID, NJ, WI, and outside the US Remarks in the notice On fees: “Laidlaw & Company (UK) Ltd. will receive a one-time activation fee of $50,000 and a cash commission and a non-accountable expense equal to 10% and 2%, respectively, of the aggregate gross proceeds.”On the use of proceeds: “To be used for payment of salary and board member fees.”Signed by Robb Knie, President and CEO. Source: SEC Form D, newest notice filed Nov 7, 2017. Read the notice at the SEC .
options SEC